Status:
WITHDRAWN
A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis
Lead Sponsor:
Loxo Oncology, Inc.
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Relapsing Multiple Sclerosis
Multiple Sclerosis
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
The main purpose of this study is to assess efficacy and safety of pirtobrutinib in participants with relapsing multiple sclerosis.
Eligibility Criteria
Inclusion
- Participants must have been diagnosed with relapsing MS
- Participants must have one of the following
- at least 1 documented relapse within the previous year, or
- at least 2 documented relapse within the previous 2 years, or
- at least 1 active Gd-enhancing brain lesion on an MRI scan in the past 6 months prior to screening.
Exclusion
- Have had a diagnosis of primary progressive MS
- Have a history of another clinically significant neurological disease
- Had a relapse of MS within 30 days prior to randomization.
Key Trial Info
Start Date :
May 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 13 2026
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT06104683
Start Date
May 1 2024
End Date
February 13 2026
Last Update
March 27 2024
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
University of South Florida
Tampa, Florida, United States, 33612
2
Clinical Trial Network
Houston, Texas, United States, 77074
3
Swedish Medical Center-501 E Hampden Ave
Seattle, Washington, United States, 98122-5698
4
Caribbean Center For Clinical Research Inc
Guaynabo, Puerto Rico, 969